Nishiyama K, Funai T, Yokota S, Ichiyama A
Department of Biochemistry, Hamamatsu University School of Medicine, Shizuoka, Japan.
J Cell Biol. 1993 Dec;123(5):1237-48. doi: 10.1083/jcb.123.5.1237.
Primary hyperoxaluria type 1 (PH 1), an inborn error of glyoxylate metabolism characterized by excessive synthesis of oxalate and glycolate, is caused by a defect in serine:pyruvate/alanine:glyoxylate aminotransferase (SPT/AGT). This enzyme is peroxisomal in human liver. Recently, we cloned SPT/AGT-cDNA from a PH 1 case, and demonstrated a point mutation of T to C in the coding region of the SPT/AGT gene encoding a Ser to Pro substitution at residue 205 (Nishiyama, K., T. Funai, R. Katafuchi, F. Hattori, K. Onoyama, and A. Ichiyama. 1991. Biochem. Biophys. Res. Commun. 176:1093-1099). In the liver of this patient, SPT/AGT was very low with respect to not only activity but also protein detectable on Western blot and immunoprecipitation analyses. Immunocytochemically detectable SPT/AGT labeling was also low, although it was detected predominantly in peroxisomes. On the other hand, the level of translatable SPT/AGT-mRNA was higher than normal, indicating that SPT/AGT had been synthesized in the patient's liver at least as effectively as in normal liver. Rapid degradation of the mutant SPT/AGT was then demonstrated in transfected COS cells and transformed Escherichia coli, accounting for the low level of immunodetectable mutant SPT/AGT in the patient's liver. The mutant SPT/AGT was also degraded much faster than normal in an in vitro system with a rabbit reticulocyte extract, and the degradation in vitro was ATP dependent. These results indicate that a single amino acid substitution in SPT/AGT found in the PH1 case leads to a reduced half-life of this protein. It appears that the mutant SPT/AGT is recognized in cells as an abnormal protein to be eliminated by degradation.
1型原发性高草酸尿症(PH 1)是一种乙醛酸代谢的先天性缺陷,其特征是草酸盐和乙醇酸盐过度合成,由丝氨酸:丙酮酸/丙氨酸:乙醛酸氨基转移酶(SPT/AGT)缺陷引起。该酶在人肝脏中位于过氧化物酶体。最近,我们从一例PH 1患者中克隆了SPT/AGT-cDNA,并在编码第205位残基(Nishiyama,K.,T. Funai,R. Katafuchi,F. Hattori,K. Onoyama,和A. Ichiyama. 1991. Biochem. Biophys. Res. Commun. 176:1093 - 1099)处的SPT/AGT基因编码区发现了一个从T到C的点突变,导致丝氨酸被脯氨酸取代。在该患者的肝脏中,SPT/AGT不仅活性很低,而且在蛋白质印迹和免疫沉淀分析中可检测到的蛋白质水平也很低。免疫细胞化学可检测到的SPT/AGT标记也很低,尽管主要在过氧化物酶体中检测到。另一方面,可翻译的SPT/AGT-mRNA水平高于正常水平,表明该患者肝脏中SPT/AGT的合成至少与正常肝脏一样有效。随后在转染的COS细胞和转化的大肠杆菌中证明了突变型SPT/AGT的快速降解,这解释了该患者肝脏中免疫可检测到的突变型SPT/AGT水平较低的原因。在含有兔网织红细胞提取物的体外系统中,突变型SPT/AGT的降解也比正常情况快得多,并且体外降解依赖于ATP。这些结果表明,在PH1病例中发现的SPT/AGT中的单个氨基酸取代导致该蛋白质的半衰期缩短。似乎突变型SPT/AGT在细胞中被识别为一种异常蛋白质,会通过降解被清除。